Researchers reported efficacy improvements with two engineered AAV8 vectors—HMR-001 and its codon-optimized counterpart HMR-001z—in a hemophilia A gene therapy study focused on restoring hemostasis. The work describes bioengineered vector performance aimed at addressing limitations seen with earlier gene delivery strategies for factor VIII replacement. (Hemophilia A is caused by factor VIII deficiency.) The update underscores ongoing optimization of AAV liver-targeted delivery for durability and effectiveness, as gene therapy developers continue to refine vector design to improve expression and safety profiles.